Board of Directors

Amos Goren


Amos is a Special Partner at Apax Partners managing the existing Apax healthcare venture portfolio and a private active investor. Amos joined Apax in 1997 and until 2007 was an Equity Partner and the Head of Apax Healthcare Europe and co-Head of Apax’s global healthcare practice. Amos led the Apax investments in Dune as Chairman since 2004. Amos directed many of Apax’s investments in medtech and biotechnology in Europe, the US and Israel including Aerovance, Astex, Cadent, Compugen. Prior to Apax, Amos was an executive involved in turnarounds of manufacturing companies in Israel and CEO of a speciality pharma company in the US which he founded and sold. Amos received his MBA from Harvard Business School, MSc from the Weizmann Institute and BSc from the Hebrew University.

Dr. Paul Enever


Paul is an adviser with Canepa U.S., where he oversees the Canepa Advanced Healthcare Fund’s strategy and investments of its Advanced Healthcare portfolio. He serves on the Boards of Directors of Cardiva Medical, Dune Medical, and Knome. Before joining Canepa, Paul was a partner with McKinsey and Company. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center. He has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.

Gary Wee


Gary is Chairman, Chief Investment Officer and Co-founder of Orchard Global Capital Group. Prior to this role, Gary was founder and Chief Executive of Newshore Capital Group and Chief Executive and Chief Investment Officer of ChapelGate Asset Management. Gary ranks as one of the world’s most successful global credit hedge fund managers, leveraging and building on his career as a derivatives trader, portfolio manager and structurer at institutions such as Deutsche Bank and the Ontario Financing Authority. He received his BA (Hons) in Economics from Queen’s University and earned his MS in Information Management from Syracuse University.

Daniel J. Levangie


Daniel Levangie, an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics, is co-founder and Managing Partner of newly formed ATON Partners, a private investment and management consulting firm. Most recently Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm acquired by Roche Diagnostics Corporation in July 2013.

Prior to the above, Mr. Levangie held a variety of executive management positions with Cytyc Corporation until the acquisition of Cytyc Corporation by Hologic, Inc. in October of 2007. Mr. Levangie held a variety of senior management positions with Cytyc Corporation including Executive Vice President and Chief Operating Officer, Chief Executive Officer and President of Cytyc Health Corporation, Executive Vice President and Chief Commercial Officer and President, Cytyc Surgical Products Division from July 2006 until October, 2007.

Prior to joining Cytyc Corporation in 1992, Mr. Levangie held a number of sales, marketing and management positions with Abbott Laboratories, North Chicago, IL.

Mr. Levangie resides in Boston, MA with his wife Joan, and is a member of the Board of Directors of Exact Sciences, Inc., Liposcience, Inc., Insulet Corporation, and Dune Medical Devices. Mr. Levangie, a graduate of Northeastern University in Boston, is a member of the Advisory Board of the Barnett Institute of Northeastern University and is a trustee of Excel Charter School.

Dr. Dan Hashimshony

Founder & Executive Board Advisor

Dan is a veteran medical device executive and entrepreneur. Prior to founding Dune he was the Chief Scientist of X-Technologies (acquired by Guidant Corp in 2003) where he led the development of a miniature X-ray emitting device for Brachytherapy. Prior to that, he worked in the semiconductors industry (Sela- Semiconductor Engineering Laboratories Ltd), focusing on the creation of novel devices for remote sensing relying on terahertz technology. As one of the pioneers of THZ radiation devices Dan was engaged in various development and academic projects in the field. Dan received his PhD in physics from the Racah Institute of Physics at Hebrew University Of Jerusalem.

- Enter Your Location -
- or -